Specific immunotherapy in allergic asthma;Spezifische immuntherapie bei allergischem asthma

Pneumologie

Volumn 57, Issue 2, 2003, Pages 84-90

  Bergmann, Karl Christian ^a,b  

^a Allergie und Asthma Klinik   (Germany)

^b Allergie und Asthma Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; CYTOKINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; POLLEN ANTIGEN;

ALLERGIC ASTHMA; BRONCHUS HYPERREACTIVITY; CAT; CLINICAL TRIAL; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; DOG; HUMAN; IMMUNOTHERAPY; MEDICAL EDUCATION; PATIENT EDUCATION; PATIENT SELECTION; PHENOTYPE; POLLEN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOM; TH2 CELL;

ALLERGENS; ASTHMA; CYTOKINES; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; PATIENT EDUCATION; TH2 CELLS;

EID: 0037325469     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37151     Document Type: Review

References (32)

1. Huss K, Huss RW. Genetics of asthma and allergies. Nurs Clin North Am 2000; 35: 695-705
2. Barnes PJ. New aspects of asthma. J Intern Med 1992; 231: 453-461
3. Burrows B, Martinez FD, Halogen M et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271-277
4. Holgate ST. The cellular and mediator basis of asthma in relation to natural history. Lancet 1997; 350: S5-S9
5. Finotto S, Galle PR, Neurath MF. Zur Immunpathogenese des Asthma bronchiale. Pneumologie 2000; 54: 412-418
6. Vignola AM, Chanez P, Godard P et al. Relationships between rhinitis and asthma. Allergy 1998; 53: 833-9
7. ARIA Workshop Report Bousquet and the ARIA Workshop Group. ARIA Zitat Langfassung: Allergic Rhinitis and its impact on Asthma (ARIA). J Allergy Clin Immunol 2001; 108: 147-336
8. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with nasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109 (2Pt1): 251-256
9. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2001; 7: 709-718
10. Abramson M, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2001; 2: CD001186
11. Riffo-Vasquez Y, Pitchford S, Spina D. Cytokines in airway inflammation. Int J Biochem Cell Biol 2000; 32: 833-853
12. Kon OM, Kay AB. T cells and chronic asthma. Int Arch Allergy Immunol 1999; 118: 133-135
13. Colavita AM, Reinach AJ, Peters SP. Contributing factors to the pathology of asthma. The TH1/TH2 paradigm. Clin Chest Med 2000; 21: 263-277
14. Muro S, Minshall EM, Hamid QA. The pathology of chronic asthma. Clin Chest Med 2000; 21: 2225-2224
15. Wills-Karp M. IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol 2001; 107: 9-18
16. Busse WW, Lemanske Jr RF. Asthma. N Engl J Med 2001; 344: 350-362
17. Durham SR, Ying S, Varney VA et al. New Insights into the mechanisms of immunotherapy. Eur Arch Orthorhinolaryngol 1995; 252: 64-67
18. Akdis CA, Blesken T, Akdis M et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106
19. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27: 1007-1015
20. Bertelsen A, Andersen JB, Christensen J et al. Immunotherapy with dog and cat extracts in children. Allergy 1989; 44: 330-335
21. Hedlin G, Graff-Lonnevig V, Heilborn H et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991; 87: 955-964
22. Walker SM, Pajno GB, Lima MT et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107: 87-93
23. Pichler CE, Marquardsen A, Sparholt S et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997; 52: 274-283
24. Varney VA, Edwards J, Tabbah K et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27: 860-867
25. Olsen OT, Larsen KR, Jacobsen L et al. A 1-year, placebo-controlled, double-blind housedust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52: 853-859
26. Dolz I, Martinez-Cocera C, Barolome JM et al. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996; 51: 489-500
27. Greiner W, Graf von der Schulenburg JM, Bergmann KC. Lebensqualität von erwachsenen Asthmapatienten. Pneumologie 1999; 53: 283-288
28. Bergmann K-Ch, Wolf H, Schnitker J et al. Lebensqualität und Compliance von Patienten bei der spezifischen Immuntherapie mit Gräserund Roggenallergenen (LQC-Studie). Allergo J 2000; 9: 480-488
29. Wettengel R, Berdel D, Hofmann D et al. Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie 1998; 52: 591-601
30. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562
31. Kleine-Tebbe J, Fuchs T, Klimek L et al. Die spezifische Immuntherapie (Hyposensenbilisierung) mit Allergenen. Pneumologie 2001; 55: 438-444
32. Sennekamp I, Fuchs T, Hornung B et al. Empfehlungen zur praktischen Durchführung der spezifischen Immuntherapie mit Allergenen (Hyposensibilisierung). Allergo I 2002; 11: 332-338